Loading...
Loading...
RedHill Biopharma Ltd.
RedHill Biopharma Ltd.. Spoken Alpha tracks RDHL's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks RDHL's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RDHL.
curl https://api.spokenalpha.com/v1/companies/RDHL| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.47 | $0.49 | -4.9% | +6.4% | +8.4% |
| Q4 FY2026 | $0.50 | $0.54 | -6.5% | +3.1% | +3.1% |
| Q3 FY2026 | $0.53 | $0.58 | -8.1% | +9.7% | +12.4% |
| Q2 FY2026 | $0.67 | $0.70 | -4.2% | +6.7% | +8.7% |
| Q1 FY2025 | $0.68 | $0.79 | -14.2% | +9.7% | +7.6% |
| Q4 FY2025 | $0.57 | $0.67 | -15.5% | +8.9% | +10.9% |
| Q3 FY2025 | $0.72 | $0.81 | -11.4% | +4.6% | +2.0% |
| Q2 FY2025 | $0.62 | $0.65 | -4.1% | -1.1% | -1.0% |
| Q1 FY2024 | $0.72 | $0.83 | -13.3% | -2.1% | +0.4% |
| Q4 FY2024 | $0.59 | $0.65 | -9.7% | +4.0% | +1.5% |